Double-targeting chimeric antigen receptor, encoding gene and recombinant expression vector

The invention discloses a double-targeting chimeric antigen receptor, which comprises a double-antigen binding region, a first hinge region, a chimeric antigen receptor T cell activation domain and a protein co-expression self-cleavage domain which are sequentially connected in series, and the doubl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: JIANG LIYING, WAN GUOQING, GU XUEFENG, SHI PING, CHEN CHUNZHOU, CHEN NIANHONG
Format: Patent
Sprache:chi ; eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator JIANG LIYING
WAN GUOQING
GU XUEFENG
SHI PING
CHEN CHUNZHOU
CHEN NIANHONG
description The invention discloses a double-targeting chimeric antigen receptor, which comprises a double-antigen binding region, a first hinge region, a chimeric antigen receptor T cell activation domain and a protein co-expression self-cleavage domain which are sequentially connected in series, and the double-antigen binding region comprises a heavy chain VH and a light chain VL of an MSLN and MUC1 single-chain antibody which are connected in series, and a second hinge region connected with the MSLN and the MUC1 single-chain antibody. The double-targeting CAR-T cell can kill tumor cells expressing double antigens, killing is more accurate and efficient, meanwhile, the off-target effect is reduced or avoided, the side effect of non-specific killing is reduced, and the anti-tumor effect is enhanced. 本发明公开了一种双靶向嵌合抗原受体,包括依次串联连接的双抗原结合区、第一铰链区、嵌合抗原受体T细胞激活域和蛋白共表达自剪切域,所述双抗原结合区包括以串联方式连接的MSLN、MUC1单链抗体的重链VH和轻链VL、及连接MSLN、MUC1单链抗体的第二铰链区。本发明的双靶向CAR-T细胞能杀伤表达双抗原的肿瘤细胞,使杀伤更为精准高效,同时降低或避免了"脱靶效应"的发生,降低了非特异杀伤的副作用,增强了抗肿瘤功效。
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN113248619A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN113248619A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN113248619A3</originalsourceid><addsrcrecordid>eNqNjLEKwjAURbs4iPoPcbdDrIiOUhUnJzeHkr5eY6B9LyRR_HxT8AOcLtxz7p0W96O82h5lMsEiObaKnm5AcKQMJ2fBKoDgk4SVApN0o5NrZN6NTIbWcXYVPj4gRies3qA8mBeTh-kjFr-cFcvz6VZfSnhpEL2hfJOa-qp1td7stnp_qP5xvqleO_0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Double-targeting chimeric antigen receptor, encoding gene and recombinant expression vector</title><source>esp@cenet</source><creator>JIANG LIYING ; WAN GUOQING ; GU XUEFENG ; SHI PING ; CHEN CHUNZHOU ; CHEN NIANHONG</creator><creatorcontrib>JIANG LIYING ; WAN GUOQING ; GU XUEFENG ; SHI PING ; CHEN CHUNZHOU ; CHEN NIANHONG</creatorcontrib><description>The invention discloses a double-targeting chimeric antigen receptor, which comprises a double-antigen binding region, a first hinge region, a chimeric antigen receptor T cell activation domain and a protein co-expression self-cleavage domain which are sequentially connected in series, and the double-antigen binding region comprises a heavy chain VH and a light chain VL of an MSLN and MUC1 single-chain antibody which are connected in series, and a second hinge region connected with the MSLN and the MUC1 single-chain antibody. The double-targeting CAR-T cell can kill tumor cells expressing double antigens, killing is more accurate and efficient, meanwhile, the off-target effect is reduced or avoided, the side effect of non-specific killing is reduced, and the anti-tumor effect is enhanced. 本发明公开了一种双靶向嵌合抗原受体,包括依次串联连接的双抗原结合区、第一铰链区、嵌合抗原受体T细胞激活域和蛋白共表达自剪切域,所述双抗原结合区包括以串联方式连接的MSLN、MUC1单链抗体的重链VH和轻链VL、及连接MSLN、MUC1单链抗体的第二铰链区。本发明的双靶向CAR-T细胞能杀伤表达双抗原的肿瘤细胞,使杀伤更为精准高效,同时降低或避免了"脱靶效应"的发生,降低了非特异杀伤的副作用,增强了抗肿瘤功效。</description><language>chi ; eng</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20210813&amp;DB=EPODOC&amp;CC=CN&amp;NR=113248619A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20210813&amp;DB=EPODOC&amp;CC=CN&amp;NR=113248619A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>JIANG LIYING</creatorcontrib><creatorcontrib>WAN GUOQING</creatorcontrib><creatorcontrib>GU XUEFENG</creatorcontrib><creatorcontrib>SHI PING</creatorcontrib><creatorcontrib>CHEN CHUNZHOU</creatorcontrib><creatorcontrib>CHEN NIANHONG</creatorcontrib><title>Double-targeting chimeric antigen receptor, encoding gene and recombinant expression vector</title><description>The invention discloses a double-targeting chimeric antigen receptor, which comprises a double-antigen binding region, a first hinge region, a chimeric antigen receptor T cell activation domain and a protein co-expression self-cleavage domain which are sequentially connected in series, and the double-antigen binding region comprises a heavy chain VH and a light chain VL of an MSLN and MUC1 single-chain antibody which are connected in series, and a second hinge region connected with the MSLN and the MUC1 single-chain antibody. The double-targeting CAR-T cell can kill tumor cells expressing double antigens, killing is more accurate and efficient, meanwhile, the off-target effect is reduced or avoided, the side effect of non-specific killing is reduced, and the anti-tumor effect is enhanced. 本发明公开了一种双靶向嵌合抗原受体,包括依次串联连接的双抗原结合区、第一铰链区、嵌合抗原受体T细胞激活域和蛋白共表达自剪切域,所述双抗原结合区包括以串联方式连接的MSLN、MUC1单链抗体的重链VH和轻链VL、及连接MSLN、MUC1单链抗体的第二铰链区。本发明的双靶向CAR-T细胞能杀伤表达双抗原的肿瘤细胞,使杀伤更为精准高效,同时降低或避免了"脱靶效应"的发生,降低了非特异杀伤的副作用,增强了抗肿瘤功效。</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjLEKwjAURbs4iPoPcbdDrIiOUhUnJzeHkr5eY6B9LyRR_HxT8AOcLtxz7p0W96O82h5lMsEiObaKnm5AcKQMJ2fBKoDgk4SVApN0o5NrZN6NTIbWcXYVPj4gRies3qA8mBeTh-kjFr-cFcvz6VZfSnhpEL2hfJOa-qp1td7stnp_qP5xvqleO_0</recordid><startdate>20210813</startdate><enddate>20210813</enddate><creator>JIANG LIYING</creator><creator>WAN GUOQING</creator><creator>GU XUEFENG</creator><creator>SHI PING</creator><creator>CHEN CHUNZHOU</creator><creator>CHEN NIANHONG</creator><scope>EVB</scope></search><sort><creationdate>20210813</creationdate><title>Double-targeting chimeric antigen receptor, encoding gene and recombinant expression vector</title><author>JIANG LIYING ; WAN GUOQING ; GU XUEFENG ; SHI PING ; CHEN CHUNZHOU ; CHEN NIANHONG</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN113248619A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2021</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>JIANG LIYING</creatorcontrib><creatorcontrib>WAN GUOQING</creatorcontrib><creatorcontrib>GU XUEFENG</creatorcontrib><creatorcontrib>SHI PING</creatorcontrib><creatorcontrib>CHEN CHUNZHOU</creatorcontrib><creatorcontrib>CHEN NIANHONG</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>JIANG LIYING</au><au>WAN GUOQING</au><au>GU XUEFENG</au><au>SHI PING</au><au>CHEN CHUNZHOU</au><au>CHEN NIANHONG</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Double-targeting chimeric antigen receptor, encoding gene and recombinant expression vector</title><date>2021-08-13</date><risdate>2021</risdate><abstract>The invention discloses a double-targeting chimeric antigen receptor, which comprises a double-antigen binding region, a first hinge region, a chimeric antigen receptor T cell activation domain and a protein co-expression self-cleavage domain which are sequentially connected in series, and the double-antigen binding region comprises a heavy chain VH and a light chain VL of an MSLN and MUC1 single-chain antibody which are connected in series, and a second hinge region connected with the MSLN and the MUC1 single-chain antibody. The double-targeting CAR-T cell can kill tumor cells expressing double antigens, killing is more accurate and efficient, meanwhile, the off-target effect is reduced or avoided, the side effect of non-specific killing is reduced, and the anti-tumor effect is enhanced. 本发明公开了一种双靶向嵌合抗原受体,包括依次串联连接的双抗原结合区、第一铰链区、嵌合抗原受体T细胞激活域和蛋白共表达自剪切域,所述双抗原结合区包括以串联方式连接的MSLN、MUC1单链抗体的重链VH和轻链VL、及连接MSLN、MUC1单链抗体的第二铰链区。本发明的双靶向CAR-T细胞能杀伤表达双抗原的肿瘤细胞,使杀伤更为精准高效,同时降低或避免了"脱靶效应"的发生,降低了非特异杀伤的副作用,增强了抗肿瘤功效。</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language chi ; eng
recordid cdi_epo_espacenet_CN113248619A
source esp@cenet
subjects BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
title Double-targeting chimeric antigen receptor, encoding gene and recombinant expression vector
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T14%3A10%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=JIANG%20LIYING&rft.date=2021-08-13&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN113248619A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true